# Semaglutide Dose, Dosage & Injection: What Trials Used | Digest > Semaglutide dose and dosage as documented in trials and labeling: the 0.25-to-2.4 mg weekly injection ladder, oral 3/7/14 mg, half-life ~1 week. Study-design facts, never personal advice. The weekly injection titration, the oral tablet schedule, and a ~one-week half-life — documented as study and label facts, not guidance. ## The gist This page describes the **semaglutide dose** and **dosage** schedules exactly as they appear in published trials and approved labeling — and nothing more. It is not a recommendation, and there are no instructions here for any individual to follow. The single most important design feature is that doses are stepped up slowly, a process called titration, because starting low and climbing reduces the nausea that otherwise drives people off the drug. The weekly injection climbs from 0.25 mg to a 2.4 mg maintenance dose over about four months in the weight studies. The pill is taken once daily on an empty stomach. And because the drug has a roughly one-week half-life, it stays in the body for about five weeks after the last dose [27]. Below, each schedule is laid out as a study fact, with the trial or label it comes from. ## Semaglutide dosage and semaglutide dose: the weekly titration ladder The subcutaneous **semaglutide injection** is given under the skin once weekly, and trials escalated the **semaglutide dose** on a fixed schedule to improve tolerability. The documented **semaglutide dosage** is a stepped ladder, not a single fixed amount. For chronic weight management, the documented ladder is: 0.25 mg once weekly for weeks 1-4, then 0.5 mg for weeks 5-8, then 1.0 mg for weeks 9-12, then 1.7 mg for weeks 13-16, then 2.4 mg as the maintenance dose — the dose used in the STEP weight-management trials [2]. For type 2 diabetes, the subcutaneous schedule documented is 0.25 mg once weekly to initiate, then 0.5 mg, then 1.0 mg as maintenance, with a 2.0 mg dose studied in the SUSTAIN FORTE program. These are the regimens the trials administered; they are stated here as study design, not as a plan for anyone. ### Semaglutide injection: route and storage The semaglutide injection is administered subcutaneously — into the fatty tissue under the skin, typically the abdomen, thigh or upper arm — once weekly on the same day each week. Trial and label handling stores pre-filled pens refrigerated before first use; the route and weekly cadence are study and labeling facts, included for completeness rather than as instructions. ## Oral semaglutide **Oral semaglutide** is a once-daily tablet co-formulated with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently raises local stomach pH so the peptide can be absorbed [17]. Even with SNAC, oral bioavailability is low — about 0.4-1% — which is exactly why the administration rules are strict [17]. The diabetes schedule documented in the PIONEER program is 3 mg daily for 30 days, then 7 mg, then 14 mg daily, taken on an empty stomach about 30 minutes before the first food, drink or other oral medication, with no more than ~120 mL of water [27]. Higher oral doses have been studied for obesity: PIONEER PLUS evaluated 25 mg and 50 mg once daily and reported greater glycemic and weight reductions than the 14 mg dose in type 2 diabetes [14]. Whether the oral and injectable forms are equivalent is addressed on the [Semaglutide effects](/effects) and FAQ pages — the short answer is that head-to-head equivalence depends on dose, and oral efficacy hinges on correct fasted administration. ## Half-life and how long it stays in the system Semaglutide's elimination half-life is approximately one week — commonly cited as ~165-168 hours — for both the subcutaneous and oral routes [27]. Because it takes roughly five half-lives for a drug to clear, semaglutide is effectively gone about five weeks after the final dose [27]. That long half-life is conferred by the strong, reversible albumin binding of its C18 fatty di-acid side chain plus the DPP-4 resistance of its Aib-8 substitution — the same structural features described on the [Semaglutide research](/research) page. One practical consequence appears in the safety record: because clearance is slow, labeling advises discontinuing well before a planned pregnancy. That caution, and others, are covered with citations on the [Semaglutide effects](/effects) page. ## Drug interactions and stability Despite slowing gastric emptying, semaglutide carries a low drug-drug-interaction risk. A clinical pharmacokinetic study found no clinically relevant effect on the exposure of co-administered metformin, warfarin, atorvastatin or digoxin [16]. A systematic review of GLP-1 receptor agonists and oral medications reached the same general conclusion — delayed gastric emptying generally does not produce clinically significant interactions — while advising monitoring for narrow-therapeutic-index oral drugs, especially during dose escalation [18]. On stability, as documented in labeling: commercial pre-filled pens are typically stored refrigerated (2-8 °C) before first use and may then be kept at room temperature (≤30 °C) for a defined in-use period (commonly cited as up to 56 days). The oral tablet is supplied co-formulated with SNAC and is not reconstituted [17]. These are handling facts from the approved product information, included for completeness. --- A data-forward reading of the semaglutide trial ledger, posted head-to-head against tirzepatide — every figure reconciled to its study, with no clinic at the desk and nothing here dosed or sold.